Categories Earnings, Health Care

Catalyst Pharmaceuticals’ Q1 results beat estimates

Catalyst Pharmaceuticals (NASDAQ: CPRX) reported first-quarter 2019 revenue and earnings that surpassed analysts’ expectations. Shares climbed around 4% in premarket hours on Monday.

Total net revenue was $12.4 million in the first quarter of 2019. Net loss was $645,000, or $0.01 per share, compared to $5.7 million, or $0.06 per share, in the same period last year.

Research and development expenses were $3.3 million, in line with the first quarter of 2018. Cost of sales was $1.7 million.

Catalyst received FDA approval of the Firdapse new drug application in November and commercially launched Firdapse in January. As of May 9, 409 unique LEMS patients were prescribed Firdapse and 380 LEMS patients were active on Firdapse.

In the second half of 2019, Catalyst expects topline results from the Phase 3 trials for MuSK-MG and CMS and in the first half of 2020, the company expects topline results for the SMA Type 3 proof of concept trial.

At March 31, 2019, Catalyst had cash and cash equivalents and investments of $50.6 million and no funded-debt. The company believes that its existing capital resources will be sufficient to support its planned operations for at least the next year.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

What to look for when CVS Health (CVS) reports Q3 earnings

Healthcare company CVS Health Corporation (NYSE: CVS) is all set to report earnings next week, with Wall Street expecting a mixed outcome. The company has been facing challenges in certain

eBay (EBAY): A few factors that helped drive growth in Q3 2024

Shares of eBay Inc. (NASDAQ: EBAY) stayed green on Friday. The stock has gained 32% year-to-date. The ecommerce leader delivered revenue and earnings growth for the third quarter of 2024,

CVX Earnings: Chevron reports lower revenue and profit for Q3 2024

Energy exploration company Chevron Corporation (NYSE: CVX) on Friday announced third-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation dropped to

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top